This page has not been authorized, sponsored, or otherwise approved or endorsed by the companies represented herein. Each of the company logos represented herein are trademarks of Microsoft Corporation; Dow Jones & Company; Nasdaq, Inc.; Forbes Media, LLC; Investor's Business Daily, Inc.; and Morningstar, Inc.
Copyright 2025 Zacks Investment Research | 101 N Wacker Drive, Floor 15, Chicago, IL 60606
At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1988 it has more than doubled the S&P 500 with an average gain of +23.75% per year. These returns cover a period from January 1, 1988 through July 7, 2025. Zacks Rank stock-rating system returns are computed monthly based on the beginning of the month and end of the month Zacks Rank stock prices plus any dividends received during that particular month. A simple, equally-weighted average return of all Zacks Rank stocks is calculated to determine the monthly return. The monthly returns are then compounded to arrive at the annual return. Only Zacks Rank stocks included in Zacks hypothetical portfolios at the beginning of each month are included in the return calculations. Zacks Ranks stocks can, and often do, change throughout the month. Certain Zacks Rank stocks for which no month-end price was available, pricing information was not collected, or for certain other reasons have been excluded from these return calculations. Zacks may license the Zacks Mutual Fund rating provided herein to third parties, including but not limited to the issuer.
Visit Performance Disclosure for information about the performance numbers displayed above.
Visit www.zacksdata.com to get our data and content for your mobile app or website.
Real time prices by BATS. Delayed quotes by Sungard.
NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed.
This site is protected by reCAPTCHA and the Google Privacy Policy, DMCA Policy and Terms of Service apply.
View All Zacks #1 Ranked Stocks
Zacks News
Teladoc Health Q2 Loss Narrower Than Expected on Declining Expenses
by Zacks Equity Research
TDOC posts narrower Q2 loss and trims costs, but shares dip as U.S. revenues and visit volumes decline.
Here's Why Fresenius (FMS) Looks Ripe for Bottom Fishing
by Zacks Equity Research
Fresenius (FMS) witnesses a hammer chart pattern, indicating support found by the stock after losing some value lately. This coupled with an upward trend in earnings estimate revisions could mean a trend reversal for the stock in the near term.
UnitedHealth Q2 Earnings Miss Estimates on Increasing Medical Costs
by Zacks Equity Research
UNH misses Q2 earnings estimates as surging medical costs slash EPS 40%, despite revenue growth and Optum Rx strength.
Universal Health Q2 Earnings Beat on Strong Acute Care Admissions
by Zacks Equity Research
UHS tops Q2 estimates with EPS up 24% as strong acute care and behavioral admissions drive revenue growth.
Here's Why Fresenius (FMS) is a Strong Value Stock
by Zacks Equity Research
Wondering how to pick strong, market-beating stocks for your investment portfolio? Look no further than the Zacks Style Scores.
Is the Options Market Predicting a Spike in Fresenius Medical Stock?
by Zacks Equity Research
Investors need to pay close attention to FMS stock based on the movements in the options market lately.
Community Health Q2 Earnings Miss on Declining Patient Days
by Zacks Equity Research
CYH posts Q2 loss despite revenue beat, as patient days and adjusted admissions decline year over year.
Molina Healthcare Q2 Earnings Miss on Rising Medical Care Costs
by Zacks Equity Research
MOH's Q2 earnings lag estimates as rising medical care costs offset gains from premiums and rate hikes.
FMS or SONVY: Which Is the Better Value Stock Right Now?
by Zacks Equity Research
FMS vs. SONVY: Which Stock Is the Better Value Option?
Elevance Health Q2 Earnings Miss Estimates on Rising Medical Costs
by Zacks Equity Research
ELV's Q2 EPS slides 12.6% y/y and misses estimates as rising Medicaid and ACA costs weigh on the results.
Encompass Health Opens Rehabilitation Hospital in Florida
by Zacks Equity Research
EHC opens its 23rd Florida rehab hospital in Daytona Beach, boosting access to care and supporting its 2025 growth plan.
Why Fresenius (FMS) is a Top Value Stock for the Long-Term
by Zacks Equity Research
The Zacks Style Scores offers investors a way to easily find top-rated stocks based on their investing style. Here's why you should take advantage.
Reasons to Add Fresenius Medical Stock to Your Portfolio Now
by Zacks Equity Research
FMS continues to gain traction on the back of acquisitions & partnerships. A tough regulatory environment raises concerns.
Zacks.com featured highlights Fresenius Medical Care, Eldorado Gold, Hope Bancorp and Heritage Insurance
by Zacks Equity Research
FMS, EGO, HOPE, and HRTG shine as high-earnings-yield value plays, with rising EPS estimates and strong fundamentals.
4 High Earnings Yield Value Stocks You Should be Owning
by Rimmi Singhi
Unlock your portfolio value by investing in stocks like FMS, EGO, HOPE and HRTG.
FMS vs. RXST: Which Stock Is the Better Value Option?
by Zacks Equity Research
FMS vs. RXST: Which Stock Is the Better Value Option?
Centene Pulls 2025 Guidance as Marketplace Growth Falters
by Zacks Equity Research
CNC pulls its 2025 forecast after a $1.8B risk adjustment shortfall. Also, weak Marketplace growth shakes investor confidence.
Cigna Expands Coverage With RhinAer & Enhances Rhinitis Treatment
by Zacks Equity Research
CI to cover RhinAer for chronic rhinitis starting Sept. 15, expanding access to a minimally invasive, office-based treatment.
Are You a Value Investor? This 1 Stock Could Be the Perfect Pick
by Zacks Equity Research
Wondering how to pick strong, market-beating stocks for your investment portfolio? Look no further than the Zacks Style Scores.
FMS Stock Likely to Gain on New Optimization Plan FME Reignite
by Zacks Equity Research
Fresenius Medical Care unveils FME Reignite, targeting one billion euros in cost savings, tech upgrades and enhanced shareholder returns.
FMS or RXST: Which Is the Better Value Stock Right Now?
by Zacks Equity Research
FMS vs. RXST: Which Stock Is the Better Value Option?
Why This 1 Value Stock Could Be a Great Addition to Your Portfolio
by Zacks Equity Research
The Zacks Style Scores offers investors a way to easily find top-rated stocks based on their investing style. Here's why you should take advantage.
Reasons to Add Fresenius Medical Stock to Your Portfolio Now
by Zacks Equity Research
FMS continues to gain traction on the back of acquisitions & partnerships. A tough regulatory environment raises concerns.
Fresenius (FMS) Upgraded to Buy: Here's Why
by Zacks Equity Research
Fresenius (FMS) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #2 (Buy).
Why This 1 Momentum Stock Could Be a Great Addition to Your Portfolio
by Zacks Equity Research
Wondering how to pick strong, market-beating stocks for your investment portfolio? Look no further than the Zacks Style Scores.